You are here

oncology

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Biopharma Dive

Ichnos Sciences

bispecific antibodies

Flag link:

Qiagen and Illumina in It for the Long Haul with 15-year Collaboration

Qiagen and Illumina in It for the Long Haul with 15-year Collaboration

Medical Devices and Diagnostics Industry

Flag link:

FDA leaders worry agency will lose out on talent in gene therapy, cancer fields

FDA leaders worry agency will lose out on talent in gene therapy, cancer fields

Biopharma Dive

Flag link:

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

Endpoints

Flag link:

Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit

Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit

Fierce Pharma

Flag link:

Oncologists listen when the FDA speaks, even after a drug hits the market

Oncologists listen when the FDA speaks, even after a drug hits the market

Endpoints

Flag link:

Pfizer expands real-world data collaboration with Flatiron Health

Pfizer expands real-world data collaboration with Flatiron Health

Pharmaceutical Business Review

Flatiron Health

real world data

Flag link:

GSK invests $120M in biopharma plant as renewed oncology bets grow

GSK invests $120M in biopharma plant as renewed oncology bets grow

Fierce Pharma

drug manufacturing

Flag link:

Overcoming Cancer Drug Resistance with A Bispecific Inhibitor

Overcoming Cancer Drug Resistance with A Bispecific Inhibitor

Xtalks

drug resistance

bispecific antibodies

Flag link:

Cancer centers stretching to keep up with pharma's oncology interest

Cancer centers stretching to keep up with pharma's oncology interest

Biopharma Dive

immuno-oncology

clinical trials

Flag link:

Mike Quigley has personal motivation leading oncology at Bristol-Myers Squibb

Mike Quigley has personal motivation leading oncology at Bristol-Myers Squibb

Bizjournals

Bristol-Myers Squibb

cancer immunotherapy

Flag link:

Evidence underpinning approval of new cancer drugs raises questions

Evidence underpinning approval of new cancer drugs raises questions

Medical Express

Flag link:

Pfizer hires ex-FDA, MD Anderson researcher as clinical oncology lead

Pfizer hires ex-FDA, MD Anderson researcher as clinical oncology lead

Fierce Biotech

Flag link:

Benevolent AI and Novartis sign AI R&D deal

Benevolent AI and Novartis sign AI R&D deal

Pharmaforum

artificial intelligence

Flag link:

The promise and pitfalls of molecular testing in oncology

The promise and pitfalls of molecular testing in oncology

Pharmaforum

emerging markets

molecular testing

Flag link:

Sanofi defends top oncology drug with Jevtana patent win

Sanofi defends top oncology drug with Jevtana patent win

Fierce Pharma

Flag link:

AstraZeneca cancer drugs build as primary care shrinks

AstraZeneca cancer drugs build as primary care shrinks

Biopharma Dive

Flag link:

Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma

Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma

Endpoints

Maya Martinez-Davis

Flag link:

Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform

Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform

Pharmaceutical Business Review

liquid microspherePH

Flag link:

Lilly shuffles executives overseeing oncology and M&A

Lilly shuffles executives overseeing oncology and M&A

Biopharma Dive

Flag link:

Pages